Atherosclerotic renal artery stenosis: Overtreated but underrated?

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Despite evidence of only moderate clinical benefit, application of renal endovascular stent procedures has increased at least four-fold in the past decade. Medicare is reviewing national coverage regarding reimbursement, questioning whether outcome data warrant many of these procedures. Several prospective, randomized trials are now in progress to compare outcomes with optimized medical therapy with and without stenting. Current imaging methods establish primarily the presence and severity of vascular occlusive disease. Optimal treatment for individual patients remains in flux and is reviewed here. Most important, nephrologists await development of tools to predict reliably when renal parenchymal injury is beyond recovery and/or when revascularization can produce meaningful salvage of kidney function.

Original languageEnglish (US)
Pages (from-to)656-659
Number of pages4
JournalJournal of the American Society of Nephrology
Volume19
Issue number4
DOIs
StatePublished - Apr 2008

Fingerprint

Renal Artery Obstruction
Kidney
Endovascular Procedures
Medicare
Vascular Diseases
Stents
Wounds and Injuries
Therapeutics

ASJC Scopus subject areas

  • Nephrology
  • Medicine(all)

Cite this

Atherosclerotic renal artery stenosis : Overtreated but underrated? / Textor, Stephen C.

In: Journal of the American Society of Nephrology, Vol. 19, No. 4, 04.2008, p. 656-659.

Research output: Contribution to journalArticle

@article{cd21748c85d048a4aa7767f0b48a2773,
title = "Atherosclerotic renal artery stenosis: Overtreated but underrated?",
abstract = "Despite evidence of only moderate clinical benefit, application of renal endovascular stent procedures has increased at least four-fold in the past decade. Medicare is reviewing national coverage regarding reimbursement, questioning whether outcome data warrant many of these procedures. Several prospective, randomized trials are now in progress to compare outcomes with optimized medical therapy with and without stenting. Current imaging methods establish primarily the presence and severity of vascular occlusive disease. Optimal treatment for individual patients remains in flux and is reviewed here. Most important, nephrologists await development of tools to predict reliably when renal parenchymal injury is beyond recovery and/or when revascularization can produce meaningful salvage of kidney function.",
author = "Textor, {Stephen C}",
year = "2008",
month = "4",
doi = "10.1681/ASN.2007111204",
language = "English (US)",
volume = "19",
pages = "656--659",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "4",

}

TY - JOUR

T1 - Atherosclerotic renal artery stenosis

T2 - Overtreated but underrated?

AU - Textor, Stephen C

PY - 2008/4

Y1 - 2008/4

N2 - Despite evidence of only moderate clinical benefit, application of renal endovascular stent procedures has increased at least four-fold in the past decade. Medicare is reviewing national coverage regarding reimbursement, questioning whether outcome data warrant many of these procedures. Several prospective, randomized trials are now in progress to compare outcomes with optimized medical therapy with and without stenting. Current imaging methods establish primarily the presence and severity of vascular occlusive disease. Optimal treatment for individual patients remains in flux and is reviewed here. Most important, nephrologists await development of tools to predict reliably when renal parenchymal injury is beyond recovery and/or when revascularization can produce meaningful salvage of kidney function.

AB - Despite evidence of only moderate clinical benefit, application of renal endovascular stent procedures has increased at least four-fold in the past decade. Medicare is reviewing national coverage regarding reimbursement, questioning whether outcome data warrant many of these procedures. Several prospective, randomized trials are now in progress to compare outcomes with optimized medical therapy with and without stenting. Current imaging methods establish primarily the presence and severity of vascular occlusive disease. Optimal treatment for individual patients remains in flux and is reviewed here. Most important, nephrologists await development of tools to predict reliably when renal parenchymal injury is beyond recovery and/or when revascularization can produce meaningful salvage of kidney function.

UR - http://www.scopus.com/inward/record.url?scp=44349113041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44349113041&partnerID=8YFLogxK

U2 - 10.1681/ASN.2007111204

DO - 10.1681/ASN.2007111204

M3 - Article

C2 - 18235081

AN - SCOPUS:44349113041

VL - 19

SP - 656

EP - 659

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 4

ER -